Page 1 of 124Free preview · 1–5

About this document

This EFSA scientific opinion reviews the tolerable upper intake level (UL) for vitamin D in infants and assesses vitamin D intake from infant formula and complementary foods in Europe. Drawing on a systematic literature review and dose-response meta-regression of supplemental vitamin D intake and serum 25(OH)D concentrations, the Panel retains a UL of 25 μg/day for infants aged up to 6 months and sets a UL of 35 μg/day for infants aged 6 to less than 12 months. These limits apply to both vitamin D2 and D3 and concern total chronic daily intake from all dietary sources. Formula containing 3 μg vitamin D/100 kcal may cause some infants younger than 4 months to exceed the UL from formula alone. Estimated high-consumer intakes among infants aged 4 - 12 months do not exceed the applicable ULs in the assessed scenarios, which exclude supplements.

Free preview text

The first 5 pages, shown as text so search engines and readers can find this document.

Page 1

SCIENTIFIC OPINION ADOPTED: dd mm 2018 doi:10.2903/j.efsa.2018.NNNN www.efsa.europa.eu/efsajournal EFSA Journal 2018;volume(issue):NNNN Update of the tolerable upper intake level for vitamin D for1 infants2 EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA),3 Dominique Turck, Jean-Louis Bresson, Barbara Burlingame, Tara Dean,4 Susan Fairweather-Tait, Marina Heinonen, Karen Ildico Hirsch-Ernst, Inge5 Mangelsdorf, Harry J McArdle, Androniki Naska, Grażyna Nowicka, Kristina6 Pentieva, Yolanda Sanz, Alfonso Siani, Anders Sjödin, Martin Stern, Daniel7 Tomé, Henk Van Loveren, Marco Vinceti, Peter Willatts, Mary Fewtrell,8 Christel Lamberg-Allardt, Hildegard Przyrembel, Davide Arcella, Céline9 Dumas, Lucia Fabiani, Laura Martino, Daniela Tomcikova and Monika10 Neuhäuser-Berthold11 Abstract12 Following a request from the European Commission (EC), the Panel on Dietetic Products, Nutrition and13 Allergies (NDA) was asked to revise the Tolerable Upper Intake Level (UL) for vitamin D for infants14 (≤ 1 year) set in 2012. From its literature review, the Panel concluded that the available evidence on15 daily vitamin D intake and the risk of adverse health outcomes (hypercalciuria, hypercalcaemia,16 nephrocalcinosis and abnormal growth patterns) cannot be used alone for deriving the UL for infants.17 The Panel conducted a meta-regression analysis of collected data, to derive a dose-response18 relationship between daily supplemental intake of vitamin D and mean achieved serum 25(OH)D19 concentrations. Considering that a serum 25(OH)D concentration of 200 nmol/L or below is unlikely to20 pose a risk of adverse health outcomes in infants, the Panel estimated the percentage of infants21 reaching a concentration above this value at different intakes of vitamin D. Based on the overall22 evidence, the Panel kept the UL of 25 μg/day for infants aged up to 6 months, and set a UL of23 35 μg/day for infants 6–12 months. The Panel was also asked to advise on the safety of the24 consumption of infant formulae with an increased maximum vitamin D content of 3 μg/100 kcal25 (Commission Delegated Regulation (EU) 2016/127 repealing Directive 2006/141/EC in 2020). For26 infants aged up to 4 months, the intake assessment showed that the use of infant formulae containing27 vitamin D at 3 μg/100 kcal may lead some infants to receive an intake above the UL of 25 μg/day28 from formulae alone without considering vitamin D supplemental intake. For infants aged 4–29 12 months, the 95th percentile of vitamin D intake (high consumers) estimated from formulae and30 foods fortified or not with vitamin D does not exceed the ULs, without considering vitamin D31 supplemental intake.32 © 2018 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on33 behalf of European Food Safety Authority.34 Keywords: vitamin D, infants, adverse health outcomes, 25(OH)D, UL , intake35 36 Requestor: European Commission37 Question number: EFSA-Q-2017-0020838 Correspondence: nda@efsa.europa.eu39 40

Page 2

UL of vitamin D for infants www.efsa.europa.eu/efsajournal 2 EFSA Journal 2018;volume(issue):NNNN Panel members: Jean-Louis Bresson, Barbara Burlingame, Tara Dean, Susan Fairweather-Tait,41 Marina Heinonen, Karen Ildico Hirsch-Ernst, Inge Mangelsdorf, Harry J McArdle, Androniki Naska,42 Monika Neuhäuser-Berthold, Grażyna Nowicka, Kristina Pentieva, Yolanda Sanz, Alfonso Siani, Anders43 Sjödin, Martin Stern, Daniel Tomé, Dominique Turck, Henk Van Loveren, Marco Vinceti and Peter44 Willatts.45 Acknowledgements: The Panel wishes to thank EFSA staff: Mathias Amundsen, Krizia Ferrini, Irene46 Muñoz Guajardo, Rita Sousa, Qingqing Sun and Ermolaos Ververis, for the support provided to this47 scientific opinion.48 Suggested citation: EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies),49 Turck D, Bresson J-L, Burlingame B, Dean T, Fairweather-Tait S, Heinonen M, Hirsch-Ernst KI,50 Mangelsdorf I, McArdle HJ, Naska A, Nowicka G, Pentieva K, Sanz Y, Siani A, Sjödin A, Stern M, Tomé51 D, Van Loveren H, Vinceti M, Willatts P, Fewtrell M, Lamberg-Allardt C, Przyrembel H, Arcella D,52 Dumas C, Fabiani L, Martino L, Tomcikova D, and Neuhäuser-Berthold M, 2017. 2018. Scientific53 opinion on the update of the tolerable upper intake level for vitamin D for infants. EFSA Journal54 2018;volume(issue):NNNN, 124 pp. doi:10.2903/j.efsa.2018.NNNN55 ISSN: 1831-473256 © 2018 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on57 behalf of European Food Safety Authority.58 This is an open access article under the terms of the Creative Commons Attribution-NoDerivs License,59 which permits use and distribution in any medium, provided the original work is properly cited and no60 modifications or adaptations are made.61 The EFSA Journal is a publication of the European Food Safety Authority, an agency of the European Union. 62

Page 3

UL of vitamin D for infants www.efsa.europa.eu/efsajournal 3 EFSA Journal 20YY;volume(issue):NNNN Summary63 Following a request from the European Commission (EC), the Panel on Dietetic Products, Nutrition and64 Allergies (NDA) revised its Opinion of 2012 on the Tolerable Upper Intake Level (UL) for vitamin D,65 regarding the UL set for infants, i.e. aged less than 1 year. The UL is the maximum level of total66 chronic daily intake of a nutrient from all sources (i.e. foods, including supplements1) judged to be67 unlikely to pose a risk of adverse health effects in humans.68 This request arises in the context of Commission Delegated Regulation (EU) 2016/1272, which will69 repeal Directive 2006/141/EC3 from 2020, and increases the maximum allowed vitamin D content from70 2.5 to 3 μg/100 kcal for infant formulae (IF), i.e. to reach the same content as for follow-on formulae71 (FoF). In order to ensure the highest level of protection of infants consuming formulae, the72 Commission seeks EFSA's advice on the safety of the consumption of formulae containing73 3 μg/100 kcal of vitamin D by infants.74 The previous EFSA Opinion of 2012 on the revision of the ULs for vitamin D set by the Scientific75 Committee on Food (SCF) in 2003 concluded that there was a paucity of data on infants on which to76 base a no- or a lowest observed adverse effect level (NOAEL or LOAEL). Having considered in77 particular available evidence on ‘high’ vitamin D intake and absence of retarded growth or78 hypercalcaemia in infants, and as newer data from intervention studies in healthy infants had not79 become available since the previous risk assessment (SCF, 2003), the Panel decided in 2012 to retain80 the UL of 25 μg vitamin D/day previously derived for infants.81 Vitamin D is the generic term for ergocalciferol (vitamin D2) and cholecalciferol (vitamin D3), which are82 present in foods. Vitamin D3 is also synthesised endogenously in the skin following exposure to UV-B83 irradiation. While for other age groups beyond infancy, the synthesis of vitamin D3 in the skin during84 the summer months may be the main source of vitamin D and may fulfil the requirement, the Panel85 considers that this may not be the case for infants, who therefore have greater reliance on dietary86 intake. In the body, vitamin D is hydroxylated in the liver to 25-hydroxyvitamin D (25(OH)D), which is87 then hydroxylated to the biologically active metabolite 1,25-hydroxyvitamin D (1,25(OH)2D) primarily88 in the kidneys. Vitamin D, 25(OH)D and 1,25(OH)2D are transported in the blood mainly by the89 vitamin D-binding protein (DBP). The principal function of 1,25(OH)2D is to maintain calcium and90 phosphorus homeostasis.91 Serum 25(OH)D concentration is used as a biomarker of vitamin D intake in populations with low92 exposure to UV-B irradiation and of vitamin D status. All analytical methods available for its93 measurement have uncertainties, which could lead to over- or underestimations. Specifically in94 infants, some analytical methods may overestimate serum concentration of 25(OH)D, due to the fact95 that they detect also the C3-epimer of 25(OH)D, which may contribute up to about 40% of total96 25(OH)D during the first three months of life (contrary to older children and adults). However, the97 metabolic role of the C3-epimer is unclear.98 Vitamin D toxicity resulting from ‘long-term’ ingestion of ‘large’ doses of vitamin D is associated with99 an increase in the serum concentration of 25(OH)D and some other vitamin D metabolites but usually100 not of the active metabolite 1,25(OH)2D. Some hypotheses for mechanisms of toxicity have been101 proposed. The presence of elevated serum free 1,25(OH)2D concentration despite normal total102 1,25(OH)2D suggests that, in states of vitamin D toxicity, 1,25(OH)2D is displaced from DBP by103 25(OH)D or other metabolites, and that this could promote entry of free 1,25(OH)2D into target cells104 where it could stimulate gene transcription.105 Based on this and previous assessments, the Panel focussed on the following four adverse health106 outcomes: hypercalciuria, hypercalcaemia, ectopic calcification e.g. nephrocalcinosis, and abnormal107 1 Prophylactic administration of vitamin D in some countries may be considered as medication. 2 Commission Delegated Regulation (EU) 2016/127 of 25 September 2015 supplementing Regulation (EU) No 609/2013 of the European Parliament and of the Council as regards the specific compositional and information requirements for infant formula and follow-on formula and as regards requirements on information relating to infant and young child feeding, OJ L 25, 2.2.2016, p. 1 3 Commission Directive 2006/141/EC of 22 December 2006 on infant formulae and follow-on formulae and amending Directive 1999/21/EC, OJ L 401, 30.12.2006, p. 1

Page 4

UL of vitamin D for infants www.efsa.europa.eu/efsajournal 4 EFSA Journal 20YY;volume(issue):NNNN growth patterns. The Panel also collected data on serum 25(OH)D concentration in relation to108 vitamin D intake or adverse health outcomes, recognising that a ‘high’ concentration is not an adverse109 health outcome per se, but can be considered as a surrogate endpoint.110 The Panel defined upfront the strategy and methodology to evaluate possible relationships between111 daily intake of vitamin D, i.e. D2 or D3 from all dietary sources including fortified foods and112 supplements, and adverse health outcomes or endpoints in infants. The Panel undertook a systematic113 literature search of trials and observational studies on full-term healthy infants, either breast-fed or114 fed with a standard IF or FoF, possibly receiving complementary foods, and appraised the risk of bias115 (RoB) of the studies.116 The Panel discussed the available evidence on the four adverse health outcomes from trials and117 observational studies. Although more data in infants are available since 2012, the Panel concludes118 that these data on daily vitamin D intake and adverse health outcomes (hypercalciuria,119 hypercalcaemia, nephrocalcinosis, and abnormal growth patterns) cannot be used alone for deriving120 the UL of vitamin D for infants. This is because of methodological limitations of the studies, including121 the use of unclear reference values for serum or urinary calcium in infants, and of single122 measurements that may not provide an indication of the risk of sustained elevated concentrations.123 Moreover, the studies showed inconsistent results, or absence of a dose-response relationship124 between vitamin D intake (or serum 25(OH)D concentration) and adverse health outcomes. The Panel125 notes the absence of data on the systematic administration of defined vitamin D doses above126 50 μg/day to healthy infants for ethical reasons. The level of daily vitamin D intake or serum 25(OH)D127 concentration that is associated with the occurrence of adverse health outcomes could not be128 determined on the basis of the available data and the Panel could not define a NOAEL for vitamin D129 intake. However, based on previous assessments and available data from infants, the Panel concludes130 that a serum 25(OH)D concentration of 200 nmol/L or below is unlikely to pose a risk of adverse131 health outcomes in healthy infants.132 Case reports described adverse health outcomes in infants associated with chronic daily administration133 of vitamin D doses of about 4.5 to 20 times the adequate intake (AI) of 10 μg/day set by EFSA in134 2016 for this age group; these outcomes were associated with elevated serum 25(OH)D135 concentrations. However, as these reports are based on incidental findings, they are not suitable to136 define a LOAEL for vitamin D in infants.137 The Panel conducted a meta-regression analysis of collected data to derive a dose-response138 relationship between daily supplemental intake of vitamin D and mean achieved serum 25(OH)D139 concentrations from data collected per arm of the trials selected through the literature search,140 adjusted for baseline serum 25(OH)D concentrations, age and duration of supplementation. This141 analysis was based on aggregated data from six trials with limited RoB, corresponding to 17 arms and142 58 time points, which used vitamin D from supplements and generally did not assess the intake of143 vitamin D from the diet. From this model, an empirical distribution of mean achieved serum 25(OH)D144 concentrations was generated from a large number of simulations. From this, a distribution of serum145 25(OH)D concentrations that may be achieved by individuals was then simulated, and the percentage146 of infants possibly reaching a concentration above 200 nmol/L was estimated for different vitamin D147 intakes.148 For infants aged up to 6 months, the Panel concludes that the available body of evidence supports149 keeping the previous UL of 25 μg/day. The Panel notes that predictions from the model support this150 conclusion. These predictions also show that, at a given intake of vitamin D, infants older than151 6 months achieve lower serum 25(OH)D concentration than infants younger than 6 months, which152 may be explained by the increase in body mass. Thus, for infants aged 6 to less than 12 months, the153 Panel considers that evidence from the predictions supports a UL of 35 μg/day.154 The Panel draws its conclusions on the UL for vitamin D from data mainly on vitamin D3, as the dose-155 response analysis to predict the percentage of individuals that would have serum 25(OH)D156 concentrations above 200 nmol/L included studies that used supplementation with vitamin D3.157 However, the updated UL of 25 and 35 μg/day applies both to vitamin D2 and D3.158 In order to characterise the risk of infants having an intake above the UL for vitamin D, the Panel159 assessed the daily vitamin D intake in Europe, considering in particular the consumption of formulae160 containing 3 μg/100 kcal of vitamin D. The intake assessment was conducted separately for infants161

Page 5

UL of vitamin D for infants www.efsa.europa.eu/efsajournal 5 EFSA Journal 20YY;volume(issue):NNNN aged up to 4 months, and for those aged 4 to less than 12 months, to account for the additional162 vitamin D intake in relation to the introduction of complementary feeding.163 Limited information was available to the Panel on the consumption of vitamin D-containing164 supplements from surveys in infants in Europe. In addition, the Panel notes that there are different165 national supplementation policies for vitamin D in infants in the EU and compliance with these policies166 may vary between countries. Furthermore, limited information was available on possible disparities167 between the labelled and the actual vitamin D content of a product (fortified foods or supplements).168 Thus, the Panel did not make any assumption regarding such disparities or regarding vitamin D169 supplementation in its intake assessment.170 For infants aged up to 4 months, according to calculations based on the maximal regulated vitamin D171 content in IF and the default ‘high’ IF consumptions set by the EFSA Scientific Committee in 2017172 (EFSA Scientific Committee et al., 2017a), the Panel concludes that, depending on the reference body173 weight used, age of the infants and energy content of formulae (without considering additional intake174 due to supplementation or possible disparities between the labelled and the actual composition of175 formulae):176 - the use of a maximum vitamin D content of 3 μg/100 kcal in IF (as per Delegated Regulation177 (EU) 2016/127) may lead some infants to consume amounts of vitamin D above the UL of178 25 μg/day from formulae alone;179 - the use of a maximum vitamin D content of 2.5 μg/100 kcal in IF (as per Directive180 2006/141/EC) does not result in intakes of vitamin D above the UL of 25 μg/day from181 formulae alone. The margin between the calculated intakes via formulae and the UL varies182 between 1 and 9 μg/day.183 For infants aged from 4 to 12 months, the intake assessment was conducted separately for consumers184 and non-consumers of IF and FoF. The intake assessment was done:185 - using food consumption data of infants from six surveys, most of them nationally186 representative of their respective EU countries;187 - and considering eight intake scenarios, based on the minimum or maximum amount of188 vitamin D in IF and FoF according to the two regulatory texts (Directive 2006/141/EC and189 Commission Delegated Regulation (EU) 2016/127) and based on the composition of foods190 fortified or not with vitamin D (without considering possible disparities between the labelled191 and the actual composition of foods), coming respectively from the EFSA Nutrient Composition192 Database, and from the Mintel Global New Products Database.193 These eight scenarios were assumed to describe situations that may occur on the EU market taking194 into account voluntarily fortified foods, different possible food patterns in infants but excluding the195 contribution from supplements, and the two extremes in the range of the vitamin D content in196 mandatorily fortified foods. They were not meant to reflect the fortification practices of the six EU197 countries that provided food consumption data. Means and 95th percentiles of estimated vitamin D198 intake were used to characterise the risk of exceeding the UL (without considering additional intake199 due to supplementation) for infants aged from 4 to 12 months:200 - For infants consuming neither formulae nor fortified foods and for those not consuming201 formulae but consuming fortified foods, the estimated means and 95th percentiles of vitamin D202 intake are below or at the AI of 10 μg/day.203 - For infants consuming IF or FoF containing the maximum amount of vitamin D of204 3 μg/100 kcal) but not consuming fortified foods, the estimated means and 95th percentiles of205 vitamin D intake are higher but do not exceed the UL of 35 μg/day (i.e. for infants 6–206 12 months). The margin between the estimated 95th percentile of vitamin D intake in formula207 consumers and the UL of 35 μg/day varies between about 15 and 22 μg/day. The margin208 calculated with the UL of 25 μg/day (i.e. for infants 4–6 months), varies between about 5 and209 12 μg/day.210 - With the additional intake of fortified foods, the estimated means and 95th percentiles of211 vitamin D intake are higher but do not exceed the UL of 35 μg/day (i.e. for infants 6–212 12 months). The margin between the estimated 95th percentile of vitamin D intake in formula213

Tags

Doxxly editorial guide

Update of the tolerable upper intake level for vitamin D for infants: summary, contents and background

This guide helps you understand the scope of Update of the tolerable upper intake level for vitamin D for infants before or alongside reading the original document. It is based on the catalogue record, credited creator, source, classification and topics shown on this page. It does not replace the original work and does not invent claims about passages that Doxxly cannot verify.

Summary and overview

Update of the tolerable upper intake level for vitamin D for infants is a 124-page documentcredited to Yusuf R. Yarrow. This EFSA scientific opinion reviews the tolerable upper intake level (UL) for vitamin D in infants and assesses vitamin D intake from infant formula and complementary foods in Europe. Drawing on a systematic literature review and dose-response meta-regression of supplemental vitamin D intake and serum 25(OH)D concentrations, the Panel retains a UL of 25 μg/day for infants aged up to 6 months and sets a UL of 35 μg/day for infants aged 6 to less than 12 months. These limits apply to both vitamin D2 and D3 and concern total chronic daily intake from all dietary sources. Formula containing 3 μg vitamin D/100 kcal may cause some infants younger than 4 months to exceed the UL from formula alone. Estimated high-consumer intakes among infants aged 4 - 12 months do not exceed the applicable ULs in the assessed scenarios, which exclude supplements. It appears in the Medicine & Wellbeing collection, which groups it with other material that readers may use for comparison and further study.

The item can be approached in several ways. A reader looking for a quick orientation can begin with the free five-page preview, inspect the page structure and use the metadata to judge relevance. Someone undertaking deeper research can work through the complete file, search its indexed text, record useful page references and compare its treatment of Scientific opinion, Vitamin D, Infant nutrition, Tolerable upper intake level, Infant formula, Dietary supplements, Nutritional risk assessment, 25(OH)D, EFSA with the related resources linked below.

Rather than reducing the work to a single claim, this page treats it as a source that should be read in context. The title, creator, publication source, licence and format all help explain what kind of evidence it may offer. Readers should distinguish the original author's statements from Doxxly's catalogue description, and should cite the original edition when using the material in academic, professional or published work.

Key topics and reader takeaways

The catalogue connects this document with Scientific opinion, Vitamin D, Infant nutrition, Tolerable upper intake level, Infant formula, Dietary supplements, Nutritional risk assessment, 25(OH)D, EFSA. These terms offer practical entry points rather than a substitute for close reading. Start by identifying the definitions, examples, arguments, tables or visual explanations attached to each topic. Then note where the creator draws connections, makes distinctions or moves from background material to a conclusion, recommendation, calculation or narrative development.

A useful reading method is to separate description from interpretation. First record what the item actually presents: names, headings, figures, formulas, quotations or stated propositions. Next consider why those details matter within the whole work. Finally compare them with another source from the same subject area. This process helps turn a long digital file into evidence that can be evaluated rather than merely skimmed.

Table of contents and reading guide

The following is an editorial content guide based on the verified catalogue topics. It is not represented as the original author's formal table of contents. Use it to organise notes while moving through the 124 pages in the player.

  1. Part 1

    Scientific opinion

    Use this section of the reading guide to identify how Scientific opinion appears in Update of the tolerable upper intake level for vitamin D for infants, note important terms, and connect the subject to the wider purpose of the work.

  2. Part 2

    Vitamin D

    Use this section of the reading guide to identify how Vitamin D appears in Update of the tolerable upper intake level for vitamin D for infants, note important terms, and connect the subject to the wider purpose of the work.

  3. Part 3

    Infant nutrition

    Use this section of the reading guide to identify how Infant nutrition appears in Update of the tolerable upper intake level for vitamin D for infants, note important terms, and connect the subject to the wider purpose of the work.

  4. Part 4

    Tolerable upper intake level

    Use this section of the reading guide to identify how Tolerable upper intake level appears in Update of the tolerable upper intake level for vitamin D for infants, note important terms, and connect the subject to the wider purpose of the work.

  5. Part 5

    Infant formula

    Use this section of the reading guide to identify how Infant formula appears in Update of the tolerable upper intake level for vitamin D for infants, note important terms, and connect the subject to the wider purpose of the work.

  6. Part 6

    Dietary supplements

    Use this section of the reading guide to identify how Dietary supplements appears in Update of the tolerable upper intake level for vitamin D for infants, note important terms, and connect the subject to the wider purpose of the work.

  7. Part 7

    Nutritional risk assessment

    Use this section of the reading guide to identify how Nutritional risk assessment appears in Update of the tolerable upper intake level for vitamin D for infants, note important terms, and connect the subject to the wider purpose of the work.

  8. Part 8

    25(OH)D

    Use this section of the reading guide to identify how 25(OH)D appears in Update of the tolerable upper intake level for vitamin D for infants, note important terms, and connect the subject to the wider purpose of the work.

When a heading in the original differs from this guide, follow the original heading in your citation. Page numbers can also vary between editions. Doxxly's direct page field is useful for navigation, but formal references should include the title, creator, source and edition details available in the file itself.

About Yusuf R. Yarrow

Doxxly credits Yusuf R. Yarrow as the author or creator of Update of the tolerable upper intake level for vitamin D for infants. This page does not add an unverified biography, job title or institutional affiliation. The attribution is preserved so readers can distinguish the creator from the hosting library and follow the original record when an external author link is available.

Author context matters because a work reflects a particular purpose, audience and point of view. Before relying on the material, consider what the creator set out to explain, when the source was produced and whether later research or revised guidance should also be consulted. For literature and philosophy, compare translations and editions; for technical material, check whether a newer version has superseded the one shown here.

About the source organisation

The recorded source for this item is efsa.europa.eu. Doxxly provides access and discovery tools but does not claim to be the original publisher unless explicitly stated. Source links, creator attribution and the recorded Publicly available file collected for editorial review licence are displayed to help readers assess provenance and permitted use.

Provenance is especially important for reports, standards, presentations and working spreadsheets. Check the original source for amendments, supporting files and current policy. A trustworthy research workflow keeps the source URL with any notes or downloaded copy, verifies important figures against the original, and avoids treating an archived document as automatically current.

Visit efsa.europa.eu

How to read and use this document

Begin with the title and opening pages, then use the guide above to decide whether to read sequentially or move to a particular topic. The Doxxly player provides previous and next navigation, a direct page field, zoom steps, fit-to-width and fit-to-page modes, rotation and fullscreen. These controls are useful when a page contains small type, a wide table, an image, a scanned layout or a dense sequence of notes.

The first five pages are open to every visitor. A plan unlocks the complete item and full-document search. Search is best used for distinctive names, technical terms or short phrases; broad words can produce too many possible contexts. When you find a useful passage, read the surrounding pages so that a sentence, chart or formula is not separated from its explanation.

If downloading is enabled, members can obtain the original PDF file. Keep the original format when formulas, slide sequencing, pagination or layout carries meaning. Respect the Publicly available file collected for editorial review terms displayed on this page, and use the rights-report link if you believe the attribution or availability needs review.

Research questions to consider

As you read Update of the tolerable upper intake level for vitamin D for infants, ask which audience the creator addresses, what problem or idea organises the work, what evidence is presented, and which assumptions remain unstated. Note whether important terms are defined consistently and whether examples represent a broader pattern or a narrow case. For quantitative material, record units, time periods, formulas and data sources. For interpretive material, separate the creator's language from your own summary.

A second set of questions concerns relevance today. Which parts remain durable, which depend on their historical or institutional setting, and what would need confirmation from a newer source? Following the tags and the Medicine & Wellbeing collection can reveal useful comparisons. Agreement between sources can strengthen confidence, while disagreement can point to changing definitions, methods, evidence or priorities.

Finally, decide what you need from the item: background knowledge, a quotation, a worked example, a model, a visual explanation or a starting bibliography. That purpose should guide the depth of reading and the notes you keep. Doxxly helps locate and navigate the source; careful interpretation remains the reader's responsibility.

Explore more Medicine & Wellbeing resources

Frequently asked questions about Update of the tolerable upper intake level for vitamin D for infants

Practical answers about reading, downloading and understanding this document on Doxxly.

More in Medicine & Wellbeing